Previously on 9/10/18, Federal Circuit affirmed the Delaware district court’s decision which found four patents invalid as obvious (reported here on this blog). In summary, Court concluded that the dosing regimen contained in the claims of the four patents would have been obvious to try considering the prior study designs and also upheld the “blocking patent” analysis.